Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Zymeworks Inc.
< Previous
1
2
3
4
Next >
Zymeworks Announces Participation in Upcoming Investor Conferences
November 21, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Tickers
ZYME
FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)
November 21, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Tickers
ZYME
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors
November 05, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Tickers
ZYME
Zymeworks Provides Corporate Update and Reports Third Quarter 2024 Financial Results
October 31, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Tickers
ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
October 29, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Tickers
ZYME
Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
October 25, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Tickers
ZYME
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers
October 21, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Tickers
ZYME
Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024
October 10, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Tickers
ZYME
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
September 18, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Tickers
ZYME
Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)
September 03, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Tickers
ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
August 22, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Tickers
ZYME
Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock
August 01, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Tickers
ZYME
Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results
August 01, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Tickers
ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
July 30, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Tickers
ZYME
Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
July 25, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Tickers
ZYME
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
July 22, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Tickers
ZYME
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
July 11, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Tickers
ZYME
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
June 17, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Tickers
ZYME
Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
June 10, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Tickers
ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
May 28, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Tickers
ZYME
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 02, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Tickers
ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
April 30, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Tickers
ZYME
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
April 11, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Tickers
ZYME
Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting
April 08, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Tickers
ZYME
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
March 28, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Tickers
ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
March 27, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Tickers
ZYME
Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
March 06, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Tickers
ZYME
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting
March 05, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Tickers
ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
February 27, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Tickers
ZYME
Zymeworks To Host Fourth Quarter and Full Year 2023 Results Conference Call
February 14, 2024
From
Zymeworks Inc.
Via
GlobeNewswire
Tickers
ZYME
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.